CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 20
- Registration Number
- NCT01176851
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 65
- Registration Number
- NCT01176903
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Bramitob® administered by PARI LC® PLUS nebulizerDrug: Bramitob® administered by PARI eFlow® rapid electronic nebulizer
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 25
- Registration Number
- NCT01116089
- Locations
- 🇲🇩
SMSI Institude of Cardiology, Chisinau, Moldova, Republic of
🇨🇿University Hospital Brno Bohunice, Brno, Czechia
🇸🇰University Hospital of L. Pasteur, Pneumonology Department, Kosice, Slovakia
A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 209
- Registration Number
- NCT01111383
- Locations
- 🇵🇱
I Oddzial Chorob Dzieciecych, Wojewodzki Specjalistyczny Szpital Dzieciecy, Kielce, Poland
🇵🇱Dzieciecy Szpital Kliniczny Akademii Medycznej, Klinika Chorob Pluc I Reumatologii, Lublin, Poland
🇵🇱Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj, Rabka Zdroj, Poland
Prospective Study on Asthma Control
Completed
- Conditions
- Asthma
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 2875
- Registration Number
- NCT01110460
Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)
Completed
- Conditions
- Respiratory Distress Syndrome, Newborn
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 972
- Registration Number
- NCT01102543
- Locations
- 🇫🇷
Laboratoire Chiesi S.A., Courbevoie, France
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 113
- Registration Number
- NCT01070524
- Locations
- 🇬🇧
The Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road, Manchester, United Kingdom
Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 457
- Registration Number
- NCT00972140
- Locations
- 🇵🇱
Prof. Iwona Graelewska Rzymowska, Lodz, Lódz, Poland
Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup
Phase 3
Terminated
- Conditions
- Croup
- Interventions
- Drug: beclomethasone dipropionate suspension for nebulisation 800 mcg/2 mlDrug: Placebo solution for nebulisation 2 ml
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 6
- Registration Number
- NCT00938353
- Locations
- 🇮🇹
Ospedale San Giuseppe Moscati, Avellino, Italy
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1199
- Registration Number
- NCT00929851
- Locations
- 🇬🇧
UCL Medical School, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath